BLTE

Belite Bio, Inc

193.55 USD

Last updated Sep 4, 20:30 UTC

Yesterday HIGH

$171.78

Yesterday LOW

$159.86

52w HIGH

$200

52w LOW

$62.18

EPS

-0.54

PE

-358.43

Next Earnings

Nov 9, 2026

Overview News Insider Transactions Government Trades Fundamentals

Belite Bio, Inc stock is up 22.11% since 30 days ago. The next earnings date is Nov 9, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 September’s closed higher than August. 100% of analysts rate it a buy.

Benzinga Insights

Mon Jun 1, 2026

Full Transcript: Belite Bio Q1 2026 Earnings Call
Benzinga Newsdesk

Tue May 26, 2026

Mizuho Maintains Outperform on Belite Bio, Lowers Price Target to $215

Mizuho analyst Graig Suvannavejh maintains Belite Bio (NASDAQ:BLTE) with a Outperform and lowers the price target from $223 to $215.
Benzinga Newsdesk

Thu May 21, 2026

HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $200 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $200 price target.
Benzinga Insights

Wed May 20, 2026

Earnings Scheduled For May 20, 2026
Benzinga Newsdesk

Wed May 20, 2026

Belite Bio Q1 EPS $(0.45) Beats $(0.63) Estimate

Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.63) by 28.57 percent. This is unchanged from the same period last year.
Benzinga Newsdesk

Mon May 18, 2026

Belite Bio's Tinlarebant Receives Orphan Drug Status From Swiss Agency For Therapeutic Products To Treat Stargardt Disease

Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio®" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet
Benzinga Newsdesk

Fri May 15, 2026

Belite Bio To Present Topline Data From Phase 3 DRAGON Study Of Stargardt Disease Type 1 Treatment At 27th Fundus Disease Forum And International Retinal Symposium

Belite Bio, Inc. (NASDAQ:BLTE), ("Belite Bio®" or the "Company"), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have
Benzinga Newsdesk

Wed Apr 22, 2026

HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $200 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $200 price target.
Benzinga Newsdesk

Tue Apr 21, 2026

Belite Bio Initiates Rolling Submission Of New Drug Application To FDA For Tinlarebant Oral Therapy To Treat Stargardt Disease Type 1

Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical
Benzinga Newsdesk

Mon Apr 13, 2026

HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $200 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $200 price target.

Morgan Stanley

Fri Aug 14, 20:02

buy

confirm
Cantor Fitzgerald

Fri Aug 14, 13:02

buy

confirm
HC Wainwright & Co.

Wed Aug 12, 13:34

buy

confirm

Advanced Data Unlock

Chuang Hao-Yuan, Chief Financial Officer

Wed Aug 12, 2026

BLTE Recent Insider Trades and Stock Chart

367 shares sold
Lin Yu-Hsin, Chief Executive Officer

Wed Aug 12, 2026

BLTE Recent Insider Trades and Stock Chart

365 shares sold